Literature DB >> 8832225

Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.

M Kilbourn1, K Frey.   

Abstract

Sensitivity to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) varies greatly among strains of mice. The numbers of vesicular monoamine transporters was examined in various brain regions of MPTP-sensitive (C57BL/6) and MPTP-insensitive (CD-1) mouse strains. In vivo radioligand binding to the vesicular monoamine transporter was studied using [11C]methoxytetrabenazine, and in vitro Bmax values determined using [3H]dihydrotetrabenazine autoradiography. Using either technique, no significant differences between the two strains were seen in the striatal binding of these radioligands to the vesicular monoamine transporter. The in vivo binding of radioligands to this transporter in the striatum was also not gender dependent. The relative resistance of CD-1 mice to the neurotoxic effects of peripheral MPTP administration thus does not appear to be a result of enhanced protection by higher levels of vesicular storage in dopaminergic neurons of the striatum.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832225     DOI: 10.1016/0014-2999(96)00252-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands.

Authors:  Xuehe Li; Yong-Woon Jung; Scott E Snyder; Joseph Blair; Philip S Sherman; Timothy Desmond; Kirk A Frey; Michael R Kilbourn
Journal:  Nucl Med Biol       Date:  2007-11-26       Impact factor: 2.408

Review 2.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 3.  PET/SPECT imaging agents for neurodegenerative diseases.

Authors:  Lin Zhu; Karl Ploessl; Hank F Kung
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

4.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

5.  Differences in Neuronal Numbers, Morphology, and Developmental Apoptosis in Mice Nigra Provide Experimental Evidence of Ontogenic Origin of Vulnerability to Parkinson's Disease.

Authors:  D J Vidyadhara; Haorei Yarreiphang; Trichur R Raju; Phalguni Anand Alladi
Journal:  Neurotox Res       Date:  2021-11-11       Impact factor: 3.911

6.  Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.

Authors:  Chi-Chang Weng; Zi-An Chen; Ko-Ting Chao; Ting-Wei Ee; Kun-Ju Lin; Ming-Huan Chan; Ing-Tsung Hsiao; Tzu-Chen Yen; Mei-Ping Kung; Ching-Han Hsu; Shiaw-Pyng Wey
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

7.  Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.

Authors:  Edith Miville-Godbout; Mélanie Bourque; Marc Morissette; Sara Al-Sweidi; Tara Smith; Asuka Mochizuki; Vijitha Senanayake; Dushmanthi Jayasinghe; Li Wang; Dayan Goodenowe; Thérèse Di Paolo
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.